Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 5

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
-  
     -  
     (2,975,117) 
     (2,975,117)
  
    Balance, September 30, 2025 
     1,641,920  
    $16,420  
    $77,764,956  
    $(73,175,649) 
    $4,605,727 
  
    Balance 
     1,641,920  
    $16,420  
    $77,764,956  
    $(73,175,649) 
    $4,605,727 

    *
    Retroactively
    restated for one-for-twenty-eight share consolidation on June 27, 2025.

See
accompanying notes to the unaudited condensed consolidated financial statements

F-3

INDAPTUS
THERAPEUTICS, INC.

Unaudited
Condensed Consolidated Statements of Cash Flows

    2025  
    2024 

    For the Nine Months Ended 

    September 30, 

    2025  
    2024 
  
    Cash flows from operating activities: 

    Net loss 
    $(12,736,466) 
    $(10,890,980)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Depreciation 
     -  
     735 
  
    Stock-based compensation 
     572,268  
     2,001,727 
  
    Change in fair value of convertible promissory notes 
     1,153,421  
     - 
  
    Changes in operating assets and liabilities: 

    Prepaid expenses and other current and non- current assets 
     463,902  
     634,419 
  
    Accounts payable and other current liabilities 
     (1,084,078) 
     (673,829)
  
    Operating lease right-of-use asset and liability, net 
     (1,790) 
     487 
  
    Net cash used in operating activities 
     (11,632,743) 
     (8,927,441)

    Cash flows from financing activities: 

    Proceeds from issuance of convertible promissory notes 
     5,714,800  
     - 
  
    Proceeds from issuance of shares of common stock and warrants